Marinomed Biotech AG (FRA:93Z) Median PS Value: €0.00 (As of Jun. 29, 2026)


FRA:93Z Marinomed Biotech AG FRA:93Z
46 GF Score
Price €8.80
GF Value €17.68
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Marinomed Biotech AG Median PS Value?

Marinomed Biotech AG FRA:93Z -5.88% 46 Median PS Value is €0.00 as of Jun. 29, 2026. GuruFocus rates FRA:93Z with a GF Score™ of 46/100 and a GF Value™ of €17.68 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 277 Biotechnology companies, Marinomed Biotech AG ranks worse than 361010.47% on this metric.

This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Marinomed Biotech AG's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €4.299. Marinomed Biotech AG's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is €0.00.

As of today (2026-06-29), Marinomed Biotech AG's share price is €8.80. Marinomed Biotech AG's Median PS Value is €0.00. Therefore, Marinomed Biotech AG's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Marinomed Biotech AG's Median PS Value or its related term are showing as below:

FRA:93Z's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.62
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Marinomed Biotech AG  (FRA:93Z) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Marinomed Biotech AG's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=8.80/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Marinomed Biotech AG Median PS Value Related Terms


Marinomed Biotech AG Median PS Value Historical Data

* Premium members only.

The historical data trend for Marinomed Biotech AG's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marinomed Biotech AG Median PS Value Chart

Marinomed Biotech AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Marinomed Biotech AG Semi-Annual Data
Dec15 Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:93Z vs VRTX, REGN, ALNY: Median PS Value Comparison

For the Biotechnology subindustry, Marinomed Biotech AG's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marinomed Biotech AG Price-to-Median-PS-Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marinomed Biotech AG's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Marinomed Biotech AG's Price-to-Median-PS-Value falls into.


FRA:93Z
46GF Score
Marinomed Biotech AG FRA:93Z
Median PS Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marinomed Biotech AG Median PS Value Calculation

Marinomed Biotech AG's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=4.299*0
=0.00

10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Marinomed Biotech AG's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €4.299.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Median PS Value →
What does a Median PS Value of €0.00 mean?
Marinomed Biotech AG (FRA:93Z) has a Median PS Value of €0.00 as of Jun. 29, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Marinomed Biotech AG and its competitors. According to the industry distribution chart, Marinomed Biotech AG ranks #999999 out of 277 companies in the Biotechnology industry.
Is Marinomed Biotech AG's Median PS Value too high?
Marinomed Biotech AG's current Median PS Value is €0.00. Based on the distribution chart, Marinomed Biotech AG ranks #999999 out of 277 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Marinomed Biotech AG has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Marinomed Biotech AG's Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Marinomed Biotech AG ranks #999999 out of 277 companies for Median PS Value. This places Marinomed Biotech AG in the lower half of its industry. The industry median Median PS Value is 0.62. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.62, based on 277 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Marinomed Biotech AG and its competitors. For the Biotechnology industry, the median Median PS Value is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Marinomed Biotech AG's current Median PS Value is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marinomed Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, Marinomed Biotech AG (FRA:93Z) is currently considered Possible Value Trap. The stock's GF Value™ is €17.68, compared to a current price of €8.80 — trading 50.2% below its estimated fair value. The current Median PS Value is €0.00. Marinomed Biotech AG's overall GF Score™ is 46/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Marinomed Biotech AG (FRA:93Z), the current Median PS Value is €0.00 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Marinomed Biotech AG (FRA:93Z) Overvalued in 2026?

Based on GuruFocus' analysis, Marinomed Biotech AG stock appears to be undervalued. The current stock price of €8.80 is trading 50.2% below its estimated GF Value™ of €17.68. GuruFocus considers Marinomed Biotech AG to be Possible Value Trap.

Key valuation signals for FRA:93Z:

  • Median PS Value: €0.00
  • GF Value™: €17.68 vs. price of €8.80 (50.2% below fair value)
  • GF Score™: 46/100 with 7 warning signs

No single metric tells the full story. See the FRA:93Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Marinomed Biotech AG Business Description

Other Exchanges MARI:Austria
Address Hovengasse 25, Korneuburg, AUT, 2100
Marinomed Biotech AG is a biopharmaceutical company focusing on the development of products in the field of respiratory and ophthalmological diseases. The company develops products for cough, cold, influenza, allergic rhinitis, and ophthalmic diseases. Its product offerings include virus-blocking nasal sprays, virus-blocking decongestant nasal sprays, virus-blocking lozenges, and virus-blocking throat sprays. The company has two reportable segments which are Virology, Immunology, and other, the majority of revenue generated from the virology segment.
46GF Score

Get the complete analysis for FRA:93Z

Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.80
Price
€17.68
GF Value